Clinical Study Validates Efficiencies of Stereotaxis Niobe® ES System Compared to Niobe II System

March 14, 2017

ST. LOUIS, March 14, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported results of a study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France, which validates the advantages of the Niobe® ES magnetic navigation system over the *Niobe* II system in terms of procedure and fluoroscopy times for atrial fibrillation (AF) ablation procedures. The study was published in the *International Journal of Cardiology* and represents the first comparison study of Stereotaxis' latest generation remote magnetic navigation system to its predecessor.

"Our aim with this study was to quantify the clinical improvements that we have experienced with complex arrhythmia ablations, specifically AF, since upgrading to the *Niobe* ES system," said Antoine Da Costa, M.D., Ph.D., Chief of the EP Unit at CHU of Saint-Étienne. "We sought to evaluate procedure duration, as well as efficacy and extent of fluoroscopic exposure associated with the *Niobe* ES system compared to the *Niobe* II in patients requiring AF ablation. Our results confirmed that the *Niobe* ES system reduced procedure time and X-ray exposure by a minimum of 30%, primarily due to the system's enhanced responsiveness."

In the Saint-Étienne study, researchers compared data on 92 consecutive patients treated with the *Niobe* ES system to 92 consecutive patients treated using the *Niobe* II system for symptomatic drug-refractory atrial fibrillation. The percentage of circumferential pulmonary vein isolation, as confirmed via spiral catheter recording during ablation, was 100%. Procedure time was significantly lower with the *Niobe* ES system than the *Niobe* II system (1.9 ± 0.4 vs. 2.7 ± 1h, $p < 0.0001$), as was X-ray duration (12 ± 4 vs. 15 ± 7 min, $p = 0.001$).

The Electrophysiology Unit (EP) at CHU of Saint-Étienne first implemented Stereotaxis technology in 2009 and installed a second *Niobe* system in 2015. They are recognized as a national center of excellence, consistently ranked in the top five for interventional cardiology in France, as well as a European center of reference in the treatment of complex arrhythmias.

The *Niobe* ES system constitutes Stereotaxis' fourth generation magnetic navigation technology, designed to improve functionality through faster computing hardware, new motion controllers and a more intuitive user interface. By creating a near real-time response to catheter movement commands, the *Niobe* ES enables an operator to navigate an ablation catheter more quickly, precisely and with little fluoroscopic guidance. The ensuing results can be faster anatomy-specific ablation procedures with significantly less X-ray exposure to the patient and physician.

About Stereotaxis

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Stereotaxis Company Contacts:

David Fischel
Chairman & Acting Chief Executive Officer

Martin C. Stammer
Chief Financial Officer

investors@stereotaxis.com

Stereotaxis, Inc.